ERBB2 and neoplasm: Moreover, HER2 expressing circulating tumor cells (CTCs) shows less sensitivity to the various chemotherapeutic agents including doxorubicin, docetaxel and 5-fluorouracil as compared to HER-negative CTCs [121].